Collectively, our findings suggest that SAMB may possess potential therapeutic efficacy against atherosclerosis by exerting anti-inflammatory effects via the modulation of the NF-κB/NLRP3 signaling pathway. This evidence concerns the gene NFKB1 and atherosclerosis.